ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-20
SponsorUniversity of Michigan

About this trial

ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.

The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.

Eligibility criteria

Qualifiers

Time between intubation and ECMO cannulation is less than 240 hours (10 days)

ECMO support type is respiratory (VV or VA cannulation)

Chest radiograph with bilateral lung disease

Disqualifiers

Previously enrolled in PROSpect

Perinatal related lung disease

Congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis

Respiratory failure caused by cardiac failure or fluid overload

Trial design

Treatments tested in this trial

  • ECMO support
  • PROSpect protocolized therapies

Treatment groups

550 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University of Michigan

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator